Sensyne is developing SENSIGHT - a real-world data analytics platform comprising data sets across a large number of sources including Sensyne’s own health system partnerships.
SENSIGHT provides a safe research environment for life science companies and analysis of fully anonymised data, aggregated for maximum deidentification, to support all stages of research and development from drug discovery through to clinical trials and post market approval and drug launch.
A common data model for data standardisation across healthcare system partners based on Sensyne’s robust gold standard data governance processes.
Increased speed of data analysis creating faster outputs for pharmaceutical companies. Currently, responding to questions about available categories of data can take several weeks with clinical AI answers taking months to produce. SENSIGHT aims to dramatically reduce these timescales to seconds and weeks.
State of the art cyber security and data processing efficiency, along with the ability to process datasources in multiple different languages.
Support pharmaceutical companies to overcome some of the issues associated with traditional clinical trials (time costs, clinical success rates, patient recruitment) by helping the development of synthetic control arms for use in Phase 2 and Phase 3 clinical trials.
Drug target identification across a range of therapeutic areas.
Analyse the performance of drugs in the wider population post regulatory approval.
Disclaimer: Sensyne Health are not responsible for external website content.
Not all Sensyne Health products are available in all territories, for further information contact head office.